Jack A. Khattar
President & CEO

The founder of Supernus Pharmaceuticals, Mr. Khattar, has 19 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies.

Prior to founding Supernus, and for more than 6 years, Mr. Khattar served as a Board member, President and CEO of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. Mr. Khattar joined Shire from CIMA, a drug delivery company that is currently a division of Cephalon, where he last served as an Executive Officer and the Chairman of the Management Committee. At CIMA he was also responsible for business development including the licensing of CIMA's technologies, corporate alliances and strategic planning.

Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex and Kodak in the US, Europe and the Middle East.

In 1985, he received his MBA from the Wharton School of the University of Pennsylvania. He is a Board member of Rockville Economic Development Inc.

Russell P. "Rip" Wilson
Vice President, Chief Financial Officer

Mr. Wilson joined Supernus in May 2009. He has worked in biotech for more than 16 years, and most recently was Senior Vice President, Chief Financial Officer and General Counsel of Iomai Corporation, which was sold to Intercell AG in August 2008. While at Iomai, he played a major role in raising more than $160 million through equity, debt and partnering financings, including Iomai's IPO in 2006, and oversaw the business and financial aspects of Iomai's $128 million contract with the U.S. Department of Health and Human Services to develop an immunostimulant patch. He also had responsibility for the quality systems and regulatory groups for a company that manufactured its own clinical materials for more than 15 trials, and had two products slated to enter Phase 3 trials in 2009. When Mr. Wilson first joined Iomai in 2000, he served as VP of Business Development before taking on the CFO role in 2002. During his tenure at Iomai, the company grew from approximately 12 employees to almost 120 employees.

Prior to joining Iomai, Mr. Wilson worked for more than 7 years at North American Vaccine, Inc., a publicly-traded company, which was sold to Baxter International in 2000. At North American Vaccine, he was a member of the senior management team where he provided legal and operational guidance as the company grew from an R&D venture into a full-scale commercial vaccine manufacturer (with over 300 employees) with one product licensed in US (1998) and a second one licensed in UK (2000). As general counsel, he negotiated the definitive acquisition agreement to sell the company to Baxter for $380 million.

Mr. Wilson also was an attorney in private practice with a firm representing venture capital and technology firms. Mr. Wilson holds MBA and JD degrees from the University of Virginia, and an BA degree from Princeton University. He is a member of the Steering Committee, Baltimore-Washington Chapter of the Association of Bioscience Financial Officers.

Woody Bryan, Ph.D.
Vice President of Business Development and Project Management

In 1991, Dr. Bryan joined the pharmaceutical industry as a Senior Scientist with Schering Plough and then worked in Business Development at AAI from 1994 – 2000 where he was Global Product Director for Pharmaceutics.

He joined Shire in January 2000 where he served as Vice President Business Development for Shire Laboratories, the Advanced Drug Delivery Division of Shire Pharmaceuticals Group, based in Rockville, Maryland. Dr. Bryan's responsibilities at Shire included business development, licensing, and Project Management for Shire's bioavailability enhancement and oral controlled release drug delivery technologies as well as Management Team member.

Dr. Bryan now serves as Vice President of Business Development, Licensing and Project Management of Supernus Pharmaceuticals following the Management Team led acquisition of substantially all of the assets of Shire Laboratories to form a specialty pharmaceutical company.

Dr. Bryan received his B.S. degree in Zoology from Clemson University, Ph.D. degree in Pharmaceutics from the Medical University of South Carolina in 1991, and an Executive Management Certificate from the University of North Carolina Kenan-Flagler Business School in 1999.

He is a member of the Licensing Executives Society (LES), American Association of Pharmaceutical Scientists (AAPS), and Controlled Release Society (CRS) and serves as an Advisory Board member to IIR's Drug Delivery Partnerships Conference.

Padmanabh P. Bhatt, Ph.D.
Vice President of Pharmaceutical Sciences

Padmanabh P. Bhatt, Ph.D. is the Vice President of Pharmaceutical Sciences responsible for the Pharmaceutical Research and Development functions as well as Intellectual Property. He is a member of the executive team that transitioned over from Shire Laboratories, Inc. to Supernus Pharmaceuticals, Inc. Dr. Bhatt was Vice President of Advanced Drug Delivery at Shire since January 2003.

Dr. Bhatt's previous experience includes being the Vice President of R&D and Chief Technology Officer at Point Biomedical Corporation in San Carlos, California and Director of Technical Development at ALZA Corporation (now a Johnson & Johnson company) in Mountain View, California. Dr. Bhatt also held positions as Group Leader of Novel Drug Delivery at Dow Corning Corporation in Midland, Michigan and Senior Scientist at Hercon Laboratories in York, Pennsylvania.

Overall, Dr. Bhatt has more than 19 years of pharmaceutical industry experience in the fields of drug delivery, controlled release, product and technology development, clinical PK, and intellectual property.

Dr. Bhatt has B.Pharm. and M.Pharm. degrees from the University of Bombay, India. He then studied under Dr. Takeru Higuchi at the University of Kansas in Lawrence, Kansas, USA where he earned M.S. and Ph.D. degrees in Pharmaceutical Chemistry.

Paolo Baroldi, M.D., Ph.D.
Senior Vice President of Clinical Development & Chief Medical Officer

Dr. Baroldi joined Supernus in January 2009 as Sr. Vice President Clinical Development and Chief Medical Officer. Dr. Baroldi has over 25 years of clinical development experience in many therapeutic areas, including psychiatry and neurology. Overall, Dr. Baroldi has contributed to the development and registration worldwide of more than 20 new medicines. He received his degree in medicine and surgery, and his Ph.D. in clinical pharmacology from the University of Milan. He also holds a degree in philosophy and history, and has a strong interest in bioethics.

Prior to joining Supernus, he worked at Vanda Pharmaceuticals, where he was Sr. Vice President and Chief Medical Officer since 2006. Previous to that role, from January 2003 to June 2006 Dr. Baroldi was Vice President Corporate Drug Development and Chairman of the R&D Board at the Chiesi Group. He led an R&D organization of 350 people across 3 sites in the US, Italy and France. From 1998 to 2002, Dr. Baroldi served as Global Head of Clinical Pharmacology at Novartis, responsible for a staff of 140 across five different sites (in France, UK, Japan, and two in the US). Before that and for more than 14 years, Dr. Baroldi held various positions in clinical development and led clinical pharmacology groups at Abbott Laboratories in the US, Glaxo, Menarini and Carlo Erba in Italy.

Tami T. Martin, R.N., Esq.
Vice President of Regulatory Affairs

Mrs. Martin joined Supernus in 2008 as Vice President of Regulatory Affairs. Mrs. Martin's career of over 20 years in regulatory affairs, clinical research and development experience, has provided her with a unique breadth of regulatory experience in multiple arenas including legal, healthcare, academic and government as well as privately and publicly-held organizations. Key professional assignments have included positions of executive leadership at Pyramid Regulatory Consulting (as President and CEO); Otsuka Maryland Research Institute (as Senior Director, Regulatory Affairs); Shire Pharmaceutical Development, Inc. (as Vice President, Regulatory Affairs), and legal positions at Hogan & Hartson as a member of the Food and Drug Practice Group, and with the Department of Health and Human Services. Mrs. Martin currently serves as an instructor for Johns Hopkins University Masters of Biotechnology and Regulatory Affairs graduate degree program, and teaches a portion of the United States Regulatory Module for TOPRA (The Organization for Professionals in Regulatory Affairs) leading to a MSc in Regulatory Affairs through the University of Wales.

Tami holds a Bachelor of Science in Nursing from Albright College in Reading, Pennsylvania; and a Juris Doctorate from Suffolk University in Boston, Massachusetts. She is a member of the Pennsylvania Bar. She holds professional associations with Regulatory Affairs Professional Society (RAPS), and the Food and Drug Law Institute.